Since supplemental grant funding comes in a variety of flavors, with different purposes, it’s not surprising that there’s confusion about which kinds of supplements MIRA grantees may apply for and which they may not. Here’s a quick run-down.
Although NIGMS is not the only source of federal funding for sepsis research, the Institute supports a substantial portfolio of research that includes both fundamental and clinical studies, from the molecular to the organismal, that emphasizes the host’s response rather than causative factors such as infection or injury. In an effort to more rapidly move NIGMS’ sepsis research program and its translation forward, we’ve issued a Request for Information (RFI) to obtain feedback, comments, novel ideas, and strategies that address the challenges and opportunities in sepsis research to accelerate advances in detection of and treatment for this condition.
A recent analysis by NIGMS staff has uncovered some promising results for women entering academic positions in the biomedical sciences. The study, which published today in the Proceedings of the National Academy of Sciences (PNAS), found that once men and women receive their first major NIH grant, their funding longevity is similar. The data contradict the common assumption that, across all career stages, women are at a large disadvantage compared to men.
The results of the analysis should be encouraging for women interested in becoming independent investigators, since the likelihood of sustaining NIH grant support may be better than commonly perceived. You can read the full study, “NIH Funding Longevity by Gender,” in the current edition of PNAS.
When NIGMS issued PAR-17-094, Maximizing Investigators’ Research Award (R35), in December 2016, we opened the established investigator MIRA mechanism to all NIGMS grantees whose single-PI R01-equivalent grants were set to terminate in the same or subsequent fiscal year as the MIRA application. The purpose of this post is to remind you of important points to keep in mind if you are eligible to apply for a MIRA. Before applying, we strongly encourage you to contact your program director, who can advise you on whether MIRA is the best funding program for you and can help estimate a project budget if your application does well in peer review.
Some key points to know if you are considering applying for a MIRA grant:
If you are a new investigator (NI) or an early stage investigator (ESI) who received a Maximizing Investigators’ Research Award (MIRA) in 2016 or 2017, you may be wondering how having a MIRA affects your ability to initiate collaborations or apply for other grants. Or, you may be curious how much flexibility you really have to deviate from your original research plans. You may also be thinking a few years ahead about a competing renewal application. Because MIRA is a new grant mechanism, NIGMS will host a webinar designed specifically to address these and other topics of interest to NI/ESI MIRA principal investigators (PIs). NIGMS program, grants management and review staff will be on hand to provide information and answer your questions. We invite NI/ESI MIRA PIs and their business officials to participate.
The webinar (link no longer available) will be held on Tuesday, September 26, from 2:00 to 3:45 p.m. EDT. The site is compatible with mobile devices. Participants will be able to submit questions through the chat function. For an audio-only presentation, call 1-866-815-0443 and enter passcode 3268089. We will post the archived webinar and slides on the MIRA webpage after the event.
Our Maximizing Investigators’ Research Award (MIRA) program is still relatively new, so it’s not surprising that NIGMS staff frequently hear misconceptions about it. This post dispels five common MIRA myths.
Myth 1: Once an investigator is awarded a MIRA, the budget will never increase.
MIRA budgets may increase. At the time of the competing renewal application, a principal investigator (PI) may request an increase in funding. MIRAs with modest budgets that have been very productive and score very well could receive budget increases. Study sections will be asked to look at budget requests, and NIGMS staff will make determinations based on the reviewers’ recommendations and available funds.
Myth 2: Early stage investigators will receive more funding for their labs if they get an R01 than if they get a MIRA.
A MIRA PI who is an early stage investigator (ESI) has a higher probability of receiving more NIGMS funding than a non-MIRA ESI. Most ESI MIRA investigators receive $250,000 in direct costs per year. A recent analysis found that the vast majority of ESIs who have received an NIGMS R01 are initially awarded $200,000 or less, and most do not go on to receive a second NIGMS R01 during the first five years of their initial award. Thus, the total NIGMS funding for most relatively new investigators is higher with a MIRA.
Myth 3: MIRA discourages collaborative research.
NIGMS strongly endorses collaborative research, and this extends to the MIRA program. However, the MIRA concept is based on the idea that NIGMS will provide support to individual investigators’ research programs. Collaborators are expected to work together because of their mutual interest in a problem. The collaborator, in most cases, will support his or her efforts with independent funding, not through a subcontract from the MIRA. In cases where a collaborator’s efforts are well-justified, essential to the research program of the MIRA and cannot be supported by the collaborator, a consortium agreement can be included in the competing application.
NIGMS also encourages scientifically productive international collaborative research efforts. However, NIGMS will only provide funding for a foreign consortium arrangement when the collaboration is essential to the PI’s research program, represents a unique scientific opportunity and cannot be supported by the collaborator.
Myth 4: MIRA PIs cannot apply for administrative supplements.
MIRA PIs are eligible for Research Supplements to Promote Diversity in Health-Related Research and may be eligible for other types of administrative supplements, such as equipment supplements offered by NIGMS through notices in the NIH Guide for Grants and Contracts. In rare situations, NIGMS may provide a supplement for a piece of equipment that could not have been anticipated at the time the application was submitted.
Myth 5: MIRA PIs cannot apply for NIGMS training grants or conference grants.
MIRA PIs are eligible to apply for grants that support research resources, training, workforce development or diversity building, clinical trials, selected cooperative agreements, SBIR/STTRs, conference grants and the portion of a center grant or a P01 that is strictly a core. In addition, a MIRA PI may receive grants from other NIH institutes or centers, although when making funding decisions NIGMS always considers an investigator’s other support, as described on our Funding Policies page.
More information, including answers to frequently asked questions, is on the MIRA page.
Not long ago, Jon Lorsch and I and several other NIGMS staff met with the leadership of one of the professional societies that represents many of our grantees. It was an opportunity to discuss NIGMS’ policies and grant mechanisms, hear about challenges that investigators face, and share ideas about how the biomedical research and training environment can be improved.
Meetings of this kind are not unusual, but they are just one of the ways we interact with the society partners related to NIGMS’ mission and, through them, communicate with their members. Another way is by attending the societies’ scientific meetings, where our staff learn about the latest research in the field, conduct grantsmanship workshops, and answer questions about the funding process.
The professional societies help us disseminate—and receive—information. For instance, they share our notices about funding opportunities and changes in NIH policies as well as respond to our requests for information. Leadership from the professional societies attend the open sessions of our Advisory Council meetings and sometimes speak during the public comment period, enhancing the exchange of information between the Institute and our constituency.
We also collaborate with professional societies on specific activities. Recent examples include meetings convened by FASEB on rigor and reproducibility and by ASBMB on research training. With ASCB, we co-organized the Life: Magnified exhibit, which brought biomedical science to a public place.
We greatly value our interactions with the societies and invite suggestions for additional ways we can partner.
This blog is one way that we reach out to the scientific community with information about research and research training policies, funding opportunities, analyses, resources, meetings and other useful news. It’s also a key way in which we get your input on our activities and plans.
When I looked back at some recent posts, I was struck by how many of them are relevant to the graduate students and postdocs in your labs. For example, the post describing our plans to modernize graduate education is a must-read for graduate students, whose ideas and perspective will further inform our efforts. The post on talking to NIH staff about your application and grant provides essential information for postdocs who will soon be independent investigators.
Please encourage your students and postdocs to subscribe to the Feedback Loop as well as to send us their suggestions for topics to cover in future posts.
Beginning at this month’s meeting of the National Advisory General Medical Sciences Council, some of the ad hoc Council members will be early career investigators. We expect to benefit from their ideas and insights, and we also hope that they will get a better understanding of the workings of Council and share what they learn with peers.
As most of you know, the Advisory Council provides the second level of review required before any grant can be funded. The Council also advises the Institute on policy and scientific matters. Regular Council members are appointed by the HHS Secretary, but for most meetings, we invite ad hoc consultants to expand the Council’s breadth of expertise. Both regular and ad hoc members are typically at fairly senior career levels—often full professors or deans. We think there is value in inviting one or two early career investigators to each Council meeting as ad hocs to provide a greater diversity of views.
We’ve identified a perfect pool to draw from: the Early Career Reviewers who have participated in a study section for NIH’s Center for Scientific Review. If you are interested in applying to this CSR program, see How to Apply.
To increase the efficiency of issuing noncompeting grant awards, we’ve changed the submission date for noncompeting continuation institutional training grant (T32 and T34) progress reports. Beginning with applications for noncompeting awards that will be made in Fiscal Year 2016:
- Progress reports for all T32 grants will be due on November 15 (rather than on December 1).
- Progress reports for all T34 grants will be due on October 15 (rather than on November 1).
There is no change in the receipt dates for competing T32 or T34 applications.